LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
About 60% of all casualties were civilians, who died as a result of disease, starvation, genocide (in particular, the Holocaust), and aerial bombing. The former Soviet Union and China suffered the most casualties. Estimates place deaths in the Soviet Union at around 23 million, while China suffered about 10 million. No country lost a greater portion of its population than Poland: approximately 5.6 million, or 16%, of its pre-war population of 34.8 million died. The Holocaust (which roughly means "burnt whole") was the deliberate and systematic murder of millions of Jews and other "unwanted" groups during World War II by the Nazi regime in Germany. Several differing views exist regarding whether it was intended to occur from the war's beginning or if the plans for it came about later. Regardless, persecution of Jews extended well before the war even started, such as during Kristallnacht (Night of Broken Glass). The Nazis used propaganda to great effect to stir up anti-Semitic feelings within ordinary Germans. After World War II, Europe was informally split into Western and Soviet spheres of influence. Western Europe later aligned as NATO, and Eastern Europe as the Warsaw Pact. There was a shift in power from Western Europe and the British Empire to the two new superpowers, the United States and the Soviet Union. These two rivals would later face off in the Cold War. In Asia, the defeat of Japan led to its democratization. China's civil war continued through and after the war, eventually resulting in the establishment of the People's Republic of China.
A 2017 systematic review and meta-analysis of 57 randomized controlled trials (RCTs) found that clonidine improved postoperative pain control. In a subset of trials reporting detailed postoperative analgesia outcomes, clonidine delayed the time until patients required additional pain medication and reduced cumulative postoperative analgesic consumption over the first 24 hours by ~24%. The same review reported that clonidine reduced the incidence of postoperative nausea and vomiting compared with placebo. Meta-analyses of α2 adrenoreceptor agonists (i.e., clonidine and dexmedetomidine) likewise report small to moderate reductions in postoperative pain intensity and opioid consumption during the first postoperative day, consistent with an opioid-sparing effect, but are limited by substantial statistical heterogeneity. In one meta-analysis of clonidine RCTs, overall adverse event rates did not differ significantly between clonidine and placebo. However, that same paper noted that a large included trial reported a higher incidence of hypotension and non-fatal cardiac arrest with clonidine, and that the available data were insufficient to rule out uncommon but serious hemodynamic complications.
== Legacy == According to The Tuscaloosa News, by the "Great Depression, the ruins of the burned statehouse were dispersed or massed into a low mound with grass on top." In 1988, "a design committee, which included architectural historian Robert Mellown...began extensive historical and archaeological research...and drew up plans to create a ruin." A historical marker in the park commemorates the school's history. The University of Alabama has a collection of papers related to the school. A poem about the old capitol was published. The western end of the 4.5-mile Riverwalk begins at Capitol Park. Located at the South West Corner in the McGuire Strickland House since 1993 is The Capitol School. It is a private school serving students from 6 weeks through High school.
Emperor Franz Joseph died of bronchitis and pneumonia at the age of 86 on 21 November 1916. "I remember the dear plump figure of Prince Lobkowitz going up to my husband," Zita later recounted, "and, with tears in his eyes, making the sign of the cross on Charles's forehead. As he did so he said, 'May God bless Your Majesty.' It was the first time we had heard the Imperial title used to us."
DAMPs can trigger re-epithelialization upon kidney injury, contributing to epithelial–mesenchymal transition, and potentially, to myofibroblast differentiation and proliferation. These discoveries suggest that DAMPs drive not only immune injury, but also kidney regeneration and renal scarring. For example, TLR2-agonistic DAMPs activate renal progenitor cells to regenerate epithelial defects in injured tubules. TLR4-agonistic DAMPs also induce renal dendritic cells to release IL-22, which also accelerates tubule re-epithelialization in acute kidney injury. Finally, DAMPs also promote renal fibrosis by inducing NLRP3, which also promotes TGF-β receptor signaling.
Sources: en.wikipedia.org
=== Telomerase uses a built-in RNA template to maintain chromosome ends === Telomerase is an enzyme that is present in all eukaryotic nuclei which serves to maintain the ends of the linear DNA in the linear chromosomes of the eukaryotic nucleus, through the addition of terminal sequences that are lost in each round of DNA replication (telomeres). Before telomerase was identified, its activity was predicted on the basis of a molecular understanding of DNA replication, which indicated that the DNA polymerases known at that time could not replicate the 3′ end of a linear chromosome, due to the absence of a template strand. Telomerase was shown to be a ribonucleoprotein enzyme that contains an RNA component that serves as a template strand, and a protein component that has reverse transcriptase activity and adds nucleotides to the chromosome ends using the internal RNA template.
The Appalachian Uplands are one of the seven physiographic divisions in Canada. Canada's GSC does not use the same classification system as the USGS below the division level. The agency does break the divisions of the Appalachian Uplands into 13 subsections that are in four different political provinces of Canada.
== Passport power == The Henley Passport Index 2019 measures how many nations a given passport can enter without a visa. It ranks 190 nations on the "strength" of its passport. Thailand was ranked 68 of 190 countries (1=strong passport; 190=weak passport). A Thai passport can gain entry to 75 nations visa free. Other ASEAN nations ranked were: Singapore, 2/189 countries visa-free; Malaysia, 12/179; Brunei, 21/165; Indonesia, 72/71; Philippines, 74/66; Cambodia, 84/54; Laos, 86/52; Vietnam, 87/51; Myanmar, 90/48. Arton Capital's Passport Index 2017 ranks 193 member nations of the UN, as well as six territories, a total of 199 passport-issuing entities, on the number of countries a given passport can enter either visa-free (VF) or with a visa on arrival (VOA). Thailand ranked 107th of 199 nations in the number of VF/VOA countries granting its citizens visa-less entry (1=most passport power; 199=least passport power). Other ASEAN nations ranked were Singapore, 3; Malaysia, 19; Brunei, 49; Philippines, 127; Indonesia, 137; Cambodia, 154; Vietnam, 159; Laos, 169; and Myanmar, 180. The Passport Index also ranks countries by the number of countries to which they extend VF or VOA visas, a "Welcoming Index". Thailand ranked 62nd of 104 nations (due to numerous ties) (1=most countries granted VF or VOA entry; 104=fewest countries granted VF or VOA entry). Other ASEAN nations ranked were Cambodia, 1; Laos, 15; Indonesia, 16; Malaysia, 17; Singapore, 18; Philippines, 19; Brunei, 70; Vietnam, 83; Myanmar, 96.
(b) Nasal dorsum and lateral nasal wall defect The size of the nasal defect (wound) occurred, in either the dorsum or the lateral wall, or both, determines the reconstructive skin-flap technique applicable to the corresponding aesthetic nasal subunits.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.